PATH Malaria Publications

Related program: Malaria

Peer-reviewed publications from PATH Malaria researchers and scientists in collaboration with external partners.


Adjei MR, Amponsa-Achiano K, Okine R, Tweneboah PO, Sally ET, Dadzie JF et al. Post introduction evaluation of the malaria vaccine implementation programme in Ghana, 2021. BMC Public Health. 2023;23(1):586

Ashton RA, Hamainza B, Lungu C, Rutagwera MI, Porter T, Bennett A et al. Effectiveness of community case management of malaria on severe malaria and inpatient malaria deaths in Zambia: a dose-response study using routine health information system data. Malar.J. 2023;22(1):96

Baral R, Levin A, Odero C, Pecenka C, Tanko BJ, Antwi-Agyei KO et al. Cost of introducing and delivering RTS,S/AS01 malaria vaccine within the malaria vaccine implementation program. Vaccine. 2023;41(8):1496–1502.

Chanda J, Wagman J, Chanda B, Kaniki T, Ng'andu M, Muyabe R et al. Feeding rates of malaria vectors from a prototype attractive sugar bait station in Western Province, Zambia: results of an entomological validation study. Malar.J. 2023;22(1):70

Das S, Máquina M, Phillips K, Cuamba N, Marrenjo D, Saúte F et al. Fine-scale spatial distribution of deltamethrin resistance and population structure of Anopheles funestus and Anopheles arabiensis populations in Southern Mozambique. Malar.J. 2023;22(1):94

Ding XC, Incardona S, Serra-Casas E, Charnaud SC, Slater HC, Domingo GJ et al. Malaria in pregnancy (MiP) studies assessing the clinical performance of highly sensitive rapid diagnostic tests (HS-RDT) for Plasmodium falciparum detection. Malar.J. 2023;22(1):60

Fabra-García A, Hailemariam S, de Jong RM, Janssen K, Teelen K, van de Vegte-Bolmer M et al. Highly potent, naturally acquired human monoclonal antibodies against Pfs48/45 block Plasmodium falciparum transmission to mosquitoes. Immunity. 2023;56(2):406–419.

Fountain A, Ye Y, Roca-Feltrer A, Rowe AK, Camara A, Fofana A et al. Surveillance as a Core Intervention to Strengthen Malaria Control Programs in Moderate to High Transmission Settings. Am J Trop Med Hyg. 2023;108(2_Suppl):8–13.

Foy BD, Some A, Magalhaes T, Gray L, Rao S, Sougue E et al. Repeat Ivermectin Mass Drug Administrations for Malaria Control II: Protocol for a Double-blind, Cluster-Randomized, Placebo-Controlled Trial for the Integrated Control of Malaria. JMIR.Res.Protoc. 2023;12:e41197

Gutman JR, Mwesigwa JN, Arnett K, Kangale C, Aaron S, Babarinde D et al. Using antenatal care as a platform for malaria surveillance data collection: study protocol. Malar.J. 2023;22(1):99

Ivanochko D, Fabra-García A, Teelen K, van de Vegte-Bolmer M, van Gemert GJ, Newton J et al. Potent transmission-blocking monoclonal antibodies from naturally exposed individuals target a conserved epitope on Plasmodium falciparum Pfs230. Immunity. 2023;56(2):420–432.

Lees RS, Fornadel C, Snetselaar J, Wagman J, Spiers A. Insecticides for Mosquito Control: Improving and Validating Methods to Strengthen the Evidence Base. Insects. 2023;14(2)

Li K, Dodds M, Spreng RL, Abraha M, Huntwork RHC, Dahora LC et al. A tool for evaluating heterogeneity in avidity of polyclonal antibodies. Front Immunol. 2023;14:1049673

Rerolle F, Dantzer E, Phimmakong T, Lover A, Hongvanthong B, Phetsouvanh R et al. Characterizing mobility patterns of forest goers in southern Lao PDR using GPS loggers. Malar.J. 2023;22(1):38

Roca-Feltrer A, Candrinho B, Ndiop M, Prosnitz D, Robertson M, Ye Y. Operationalizing Surveillance as a Malaria Intervention: Data Use for Action. Am J Trop Med Hyg. 2023;108(2_Suppl):3

Tottey S, Shoji Y, Mark JR, Musiychuk K, Chichester JA, Miura K et al. Engineering of a plant-produced virus-like particle to improve the display of the Plasmodium falciparum Pfs25 antigen and transmission-blocking activity of the vaccine candidate. Vaccine. 2023;41(4):938–944.


Alkema M, Yap XZ, de Jong GM, Reuling IJ, de MQ, van CR et al. Controlled human malaria infections by mosquito bites induce more severe clinical symptoms than asexual blood-stage challenge infections. EBioMedicine. 2022;77:103919

Attractive Targeted Sugar Bait Phase III Trial Group. Attractive targeted sugar bait phase III trials in Kenya, Mali, and Zambia. Trials. 2022;23:640.

Beutler N, Pholcharee T, Oyen D, Flores-Garcia Y, MacGill RS, Garcia E et al. A novel CSP C-terminal epitope targeted by an antibody with protective activity against Plasmodium falciparum. PLoS Pathog. 2022;18(3):e1010409

Borkovska O, Pollard D, Hamainza B, Kooma E, Renn S, Schmidt J et al. Developing High-Resolution Population and Settlement Data for Impactful Malaria Interventions in Zambia. J Environ Public Health. 2022;2022:2941013

Bridges DJ, Miller JM, Chalwe V, Moonga H, Hamainza B, Steketee RW et al. Reactive focal drug administration associated with decreased malaria transmission in an elimination setting: Serological evidence from the cluster-randomized CoRE study. PLOS Glob.Public Health. 2022;2(12):e0001295

Brito-Sousa JD, Murta F, Vitor-Silva S, Sampaio V, Mendes M, Souza B et al. Quantitative G6PD Deficiency Screening in Routine Malaria Diagnostic Units in the Brazilian Amazon (SAFEPRIM): An Operational Mixed-Methods Study. Pathogens. 2022;11(11)

van der Boor SC, Smit MJ, van Beek SW, Ramjith J, Teelen K, van d, V et al. Safety, tolerability, and Plasmodium falciparum transmission-reducing activity of monoclonal antibody TB31F: a single-centre, open-label, first-in-human, dose-escalation, phase 1 trial in healthy malaria-naive adults. Lancet Infect Dis. 2022

Dabira ED, Soumare HM, Conteh B, Ceesay F, Ndiath MO, Bradley J et al. Mass drug administration of ivermectin and dihydroartemisinin-piperaquine against malaria in settings with high coverage of standard control interventions: a cluster-randomised controlled trial in The Gambia. Lancet Infect Dis. 2022;22(4):519–528.

Fraser M, Miller JM, Silumbe K, Hainsworth M, Mudenda M, Hamainza B et al. Evaluating the Impact of Programmatic Mass Drug Administration for Malaria in Zambia Using Routine Incidence Data. J Infect Dis. 2022;225(8):1415–1423.

Gansane A, Candrinho B, Mbituyumuremyi A, Uhomoibhi P, NFale S, Mohammed AB et al. Design and methods for a quasi-experimental pilot study to evaluate the impact of dual active ingredient insecticide-treated nets on malaria burden in five regions in sub-Saharan Africa. Malar J. 2022;21(1):19

Grant J, Sagara I, Zongo I, Cairns M, Yerbanga RS, Diarra M et al. Impact of seasonal RTS,S/AS01(E) vaccination plus seasonal malaria chemoprevention on the nutritional status of children in Burkina Faso and Mali. Malar J. 2022;21(1):59

Greenwood B, Zongo I, Dicko A, Chandramohan D, Snow RW, Ockenhouse C. Resurgent and delayed malaria. Malar J. 2022;21(1):77

Gutman JR, Thwing J, Mwesigwa J, McElroy P, Robertson M. Routine Healthcare Facility- and Antenatal Care-based Malaria Surveillance: Challenges and Opportunities. Am J Trop Med Hyg. 2022

Huang WC, Mabrouk MT, Zhou L, Baba M, Tachibana M, Torii M et al. Vaccine co-display of CSP and Pfs230 on liposomes targeting two Plasmodium falciparum differentiation stages. Commun.Biol. 2022;5(1):773

Jang IK, Jimenez A, Rashid A, Barney R, Golden A, Ding XC et al. Comparison of two malaria multiplex immunoassays that enable quantification of malaria antigens. Malar J. 2022;21(1):176

de Jong RM, Singh SK, Teelen K, van d, V, van Gemert GJ, Stone WJR et al. Heterologous Expression and Evaluation of Novel Plasmodium falciparum Transmission Blocking Vaccine Candidates. Front.Immunol. 2022;13:909060

Kho S, Anstey NM, Barber BE, Piera K, William T, Kenangalem E et al. Diagnostic performance of a 5-plex malaria immunoassay in regions co-endemic for Plasmodium falciparum, P. vivax, P. knowlesi, P. malariae and P. ovale. Sci Rep. 2022;12(1):7286

Lees RS, Armistead JS, Azizi S, Constant E, Fornadel C, Gimnig JE et al. Strain Characterisation for Measuring Bioefficacy of ITNs Treated with Two Active Ingredients (Dual-AI ITNs): Developing a Robust Protocol by Building Consensus. Insects. 2022;13(5)

Ley B, Winasti SA, Kibria MG, Armstrong J, Bancone G, Bei AK et al. Repeatability and reproducibility of a handheld quantitative G6PD diagnostic. PLoS Negl Trop Dis. 2022;16(2):e0010174

Lourenço GE, Chissaque A, Pecenka C, Clark A, Vaz B, Banze A et al. Cost-effectiveness of rotavirus vaccination in Mozambique. Vaccine. 2022;40(36):5338–5346.

Marquart L, Webb L, O'Rourke P, Gatton ML, Hsiang MS, Kalnoky M et al. The in-vivo dynamics of Plasmodium falciparum HRP2: implications for the use of rapid diagnostic tests in malaria elimination. Malar J. 2022;21(1):233

McLeod B, Mabrouk MT, Miura K, Ravichandran R, Kephart S, Hailemariam S et al. Vaccination with a structure-based stabilized version of malarial antigen Pfs48/45 elicits ultra-potent transmission-blocking antibody responses. Immunity. 2022;55(9):1680–1692.

Miura K, Pham TP, Lee SM, Plieskatt J, Diouf A, Sagara I et al. Development and Qualification of an Antigen Integrity Assay for a Plasmodium falciparum Malaria Transmission Blocking Vaccine Candidate, Pfs230. Vaccines (Basel.). 2022;10(10)

Miura K, Takashima E, Pham TP, Deng B, Zhou L, Huang WC et al. Elucidating functional epitopes within the N-terminal region of malaria transmission blocking vaccine antigen Pfs230. NPJ Vaccines. 2022;7(1):4

Mumba N, Njuguna P, Chi P, Marsh V, Awuor E, Hamaluba M et al. Undertaking Community Engagement for a Controlled Human Malaria Infection Study in Kenya: Approaches and Lessons Learnt. Front.Public Health. 2022;10:793913

Pfeffer DA, Satyagraha AW, Sadhewa A, Alam MS, Bancone G, Boum Y et al. Genetic Variants of Glucose-6-Phosphate Dehydrogenase and Their Associated Enzyme Activity: A Systematic Review and Meta-Analysis. Pathogens. 2022;11(9)

Pons-Duran C, Mombo-Ngoma G, Macete E, Desai M, Kakolwa MA, Zoleko-Manego R et al. Burden of malaria in pregnancy among adolescent girls compared to adult women in 5 sub-Saharan African countries: A secondary individual participant data meta-analysis of 2 clinical trials. PLoS Med. 2022;19(9):e1004084

Rumaseb A, Marfurt J, Kho S, Kahn M, Price RN, Ley B. A fluorometric assay to determine the protective effect of glucose-6-phosphate dehydrogenase (G6PD) against a Plasmodium spp. infection in females heterozygous for the G6PD gene: proof of concept in Plasmodium falciparum. BMC Res Notes. 2022;15(1):76

Sagara I, Zongo I, Cairns M, Yerbanga RS, Mahamar A, Nikièma F et al. The Anti-Circumsporozoite Antibody Response of Children to Seasonal Vaccination With the RTS,S/AS01E Malaria Vaccine. Clin Infect Dis. 2022;75(4):613–622.

Samuels AM, Ansong D, Kariuki SK, Adjei S, Bollaerts A, Ockenhouse C et al. Efficacy of RTS,S/AS01(E) malaria vaccine administered according to different full, fractional, and delayed third or early fourth dose regimens in children aged 5-17 months in Ghana and Kenya: an open-label, phase 2b, randomised controlled trial. Lancet Infect Dis. 2022;22(9):1329–1342.

Samuels AM, Towett O, Seda B, Wiegand RE, Otieno K, Chomba M et al. Diagnostic Performance of Loop-Mediated Isothermal Amplification and Ultrasensitive Rapid Diagnostic Tests for Malaria Screening Among Pregnant Women in Kenya. J Infect Dis. 2022;226(4):696–707.

Sherrard-Smith E, Ngufor C, Sanou A, Guelbeogo MW, N'Guessan R, Elobolobo E et al. Inferring the epidemiological benefit of indoor vector control interventions against malaria from mosquito data. Nat Commun. 2022;13(1):3862

Slater HC, Ding XC, Knudson S, Bridges DJ, Moonga H, Saad NJ et al. Performance and utility of more highly sensitive malaria rapid diagnostic tests. BMC Infect Dis. 2022;22(1):121

Tairou F, Nawaz S, Tahita MC, Herrera S, Faye B, Tine RCK. Malaria prevention knowledge, attitudes, and practices (KAP) among adolescents living in an area of persistent transmission in Senegal: Results from a cross-sectional study. PLoS One. 2022;17(12):e0274656

Wagman J, Fornadel C, Okumu F. Some residual malaria transmission may be "out of control" but "within reach" of current tools. Proc.Natl.Acad.Sci U S A. 2022;119(38):e2210568119

Wittenauer R, Nowak S, Luter N. Price, quality, and market dynamics of malaria rapid diagnostic tests: analysis of Global Fund 2009-2018 data. Malar J. 2022;21(1):12

Yukich J, Digre P, Scates S, Boydens L, Obi E, Moran N et al. Incremental cost and cost-effectiveness of the addition of indoor residual spraying with pirimiphos-methyl in sub-Saharan Africa versus standard malaria control: results of data collection and analysis in the Next Generation Indoor Residual Sprays (NgenIRS) project, an economic-evaluation. Malar J. 2022;21(1):185


Alkema M, Reuling IJ, de Jong GM, Lanke K, Coffeng LE, van Gemert GJ, et al. A Randomized Clinical Trial to Compare Plasmodium falciparum Gametocytemia and Infectivity After Blood-Stage or Mosquito Bite-Induced Controlled Malaria Infection. J Infect Dis. 2021;224(7):1257–1265.

Alonso S, Chaccour CJ, Wagman J, Candrinho B, Muthoni R, Saifodine A, et al. Cost and cost-effectiveness of indoor residual spraying with pirimiphos-methyl in a high malaria transmission district of Mozambique with high access to standard insecticide-treated nets. Malar J. 2021;20(1):143.

Baral R, Levin A, Odero C, Pecenka C, Tabu C, Mwendo E, et al. Costs of continuing RTS,S/ASO1E malaria vaccination in the three malaria vaccine pilot implementation countries. PLoS One. 2021;16(1):e0244995.

Barney R, Velasco M, Cooper CA, Rashid A, Kyle DE, Moon RW, et al. Diagnostic Characteristics of Lactate Dehydrogenase on a Multiplex Assay for Malaria Detection Including the Zoonotic Parasite Plasmodium knowlesi. Am J Trop Med Hyg. 2021;106(1):275–282.

Brito-Sousa JD, Murta F, Vitor-Silva S, Sampaio VS, Mendes MO, Brito MAM, et al. Real-life implementation of a G6PD deficiency screening qualitative test into routine vivax malaria diagnostic units in the Brazilian Amazon (SAFEPRIM study). PLoS Negl Trop Dis. 2021;15(5):e0009415.

Chaccour C, Zulliger R, Wagman J, Casellas A, Nacima A, Elobolobo E, et al. Incremental impact on malaria incidence following indoor residual spraying in a highly endemic area with high standard ITN access in Mozambique: results from a cluster-randomized study. Malar J. 2021;20(1):84.

Chandramohan D, Zongo I, Sagara I, Cairns M, Yerbanga RS, Diarra M, et al. Seasonal Malaria Vaccination with or without Seasonal Malaria Chemoprevention. N Engl J Med. 2021;385(11):1005–1017.

Chaudhury S, MacGill RS, Early AM, Bolton JS, King CR, Locke E, et al. Breadth of humoral immune responses to the C-terminus of the circumsporozoite protein is associated with protective efficacy induced by the RTS,S malaria vaccine. Vaccine. 2021;39(6):968–975.

Dabira ED, Soumare HM, Conteh B, Ceesay F, Ndiath MO, Bradley J, et al. Mass drug administration of ivermectin and dihydroartemisinin-piperaquine against malaria in settings with high coverage of standard control interventions: a cluster-randomised controlled trial in The Gambia. Lancet Infect Dis. 2022;22(4):519–528.

Das J, Fallon JK, Yu TC, Michell A, Suscovich TJ, Linde C, et al. Delayed fractional dosing with RTS,S/AS01 improves humoral immunity to malaria via a balance of polyfunctional N. Med (N Y). 2021;2(11):1269–1286.

de Jong RM, Meerstein-Kessel L, Da DF, Nsango S, Challenger JD, van d, V, et al. Monoclonal antibodies block transmission of genetically diverse Plasmodium falciparum strains to mosquitoes. NPJ Vaccines. 2021;6(1):101.

Gerth-Guyette E, Adissu W, Brito M, Garbin E, Macedo M, Sharma A, et al. Usability of a point-of-care diagnostic to identify glucose-6-phosphate dehydrogenase deficiency: a multi-country assessment of test label comprehension and results interpretation. Malar J. 2021;20(1):307.

Hamer DH, Miller JM. Why Did Mass Test and Treat Have No Effect on Malaria Prevalence in Western Kenya? Clin Infect Dis. 2021;72(11):1936–1937.

Jackson CL, Colborn K, Gao D, Rao S, Slater HC, Parikh S, et al. Design and analysis of a 2-year parallel follow-up of repeated ivermectin mass drug administrations for control of malaria: Small sample considerations for cluster-randomized trials with count data. Clin Trials . 2021;18(5):582–593.

Jang IK, Aranda S, Barney R, Rashid A, Helwany M, Rek JC, et al. Assessment of Plasmodium antigens and CRP in dried blood spots with multiplex malaria array. J Parasit Dis. 2021;45(2):479–489.

Keating J, Yukich JO, Miller JM, Scates S, Hamainza B, Eisele TP, et al. Retrospective evaluation of the effectiveness of indoor residual spray with pirimiphos-methyl (Actellic) on malaria transmission in Zambia. Malar J. 2021;20(1):173.

Moon JE, Greenleaf ME, Regules JA, Debois M, Duncan EH, Sedegah M, et al. A phase IIA extension study evaluating the effect of booster vaccination with a fractional dose of RTS,S/AS01(E) in a controlled human malaria infection challenge. Vaccine. 2021;39(43):6398–6406.

Mulenga MC, Sitali L, Ciubotariu II, Hawela MB, Hamainza B, Chipeta J, et al. Decreased prevalence of the Plasmodium falciparum Pfcrt K76T and Pfmdr1 and N86Y mutations post-chloroquine treatment withdrawal in Katete District, Eastern Zambia. Malar J. 2021;20(1):329.

Mwenda MC, Fola AA, Ciubotariu II, Mulube C, Mambwe B, Kasaro R, et al. Performance evaluation of RDT, light microscopy, and PET-PCR for detecting Plasmodium falciparum malaria infections in the 2018 Zambia National Malaria Indicator Survey. Malar J. 2021;20(1):386.

Nega D, Abera A, Gidey B, Mekasha S, Abebe A, Dillu D, et al. Baseline malaria prevalence at the targeted pre-elimination districts in Ethiopia. BMC Public Health. 2021;21(1):1996.

Ortiz DI, Piche-Ovares M, Romero-Vega LM, Wagman J, Troyo A. The Impact of Deforestation, Urbanization, and Changing Land Use Patterns on the Ecology of Mosquito and Tick-Borne Diseases in Central America. Insects. 2021;13(1).

Pal S, Myburgh J, Bansil P, Hann A, Robertson L, Gerth-Guyette E, et al. Reference and point-of-care testing for G6PD deficiency: Blood disorder interference, contrived specimens, and fingerstick equivalence and precision. PLoS One. 2021;16(9):e0257560.

Pholcharee T, Oyen D, Flores-Garcia Y, Gonzalez-Paez G, Han Z, Williams KL, et al. Structural and biophysical correlation of anti-NANP antibodies with in vivo protection against P. falciparum. Nat Commun. 2021;12(1):1063.

Ruwanpura VSH, Nowak S, Gerth-Guyette E, Theodora M, Dysoley L, Haile M, et al. Further evidence needed to change policy for the safe and effective radical cure of vivax malaria: Insights from the 2019 annual APMEN Vivax Working Group meeting. Asia Pac Policy Stud. 2021;8(2):208–242.

Sagara I, Zongo I, Cairns M, Yerbanga RS, Mahamar A, Nikièma F, et al. The Anti-Circumsporozoite Antibody Response Of Children To Seasonal Vaccination With The Rts,S/As01e Malaria Vaccine. Clin Infect Dis. 2021.

Seaton KE, Spreng RL, Abraha M, Reichartz M, Rojas M, Feely F, et al. Subclass and avidity of circumsporozoite protein specific antibodies associate with protection status against malaria infection. NPJ Vaccines. 2021;6(1):110.

Singh SK, Plieskatt J, Chourasia BK, Singh V, Bengtsson KL, Reimer JM, et al. Preclinical development of a Pfs230-Pfs48/45 chimeric malaria transmission-blocking vaccine. NPJ Vaccines. 2021;6(1):120.

Sitali L, Mwenda MC, Miller JM, Bridges DJ, Hawela MB, Hamainza B, et al. Data on selected antimalarial drug resistance markers in Zambia. Data.Brief. 2021;34:106650.

Sy M, Badiane AS, Deme AB, Gaye A, Ndiaye T, Fall FB, et al. Genomic investigation of atypical malaria cases in Kanel, northern Senegal. Malar J. 2021;20(1):103.

Tripathi AK, Oakley MS, Verma N, Mlambo G, Zheng H, Meredith SM, et al. Plasmodium falciparum Pf77 and male development gene 1 as vaccine antigens that induce potent transmission-reducing antibodies. Sci Transl.Med. 2021;13(597).

Wagman JM, Varela K, Zulliger R, Saifodine A, Muthoni R, Magesa S, et al. Reduced exposure to malaria vectors following indoor residual spraying of pirimiphos-methyl in a high-burden district of rural Mozambique with high ownership of long-lasting insecticidal nets: entomological surveillance results from a cluster-randomized trial. Malar J. 2021;20(1):54.

Whittaker C, Slater H, Nash R, Bousema T, Drakeley C, Ghani AC, et al. Global patterns of submicroscopic Plasmodium falciparum malaria infection: insights from a systematic review and meta-analysis of population surveys. Lancet Microbe. 2021;2(8):e366–e374.

Young WC, Carpp LN, Chaudhury S, Regules JA, Bergmann-Leitner ES, Ockenhouse C, et al. Comprehensive Data Integration Approach to Assess Immune Responses and Correlates of RTS,S/AS01-Mediated Protection From Malaria Infection in Controlled Human Malaria Infection Trials. Front.Big.Data. 2021;4:672460.

Zobrist S, Brito M, Garbin E, Monteiro WM, Clementino FS, Macedo M, et al. Evaluation of a point-of-care diagnostic to identify glucose-6-phosphate dehydrogenase deficiency in Brazil. PLoS Negl Trop Dis. 2021;15(8):e0009649.


Alkema M, Reuling IJ, de Jong GM, Lanke K, Coffeng LE, van Gemert GJ, et al. Corrigendum to: A Randomized Clinical Trial to Compare Plasmodium falciparum Gametocytemia and Infectivity After Blood-Stage or Mosquito Bite-Induced Controlled Malaria Infection. J Infect Dis. 2020;222(8):1416.

Bridges DJ, Chishimba S, Mwenda M, Winters AM, Slawsky E, Mambwe B, et al. The use of spatial and genetic tools to assess Plasmodium falciparum transmission in Lusaka, Zambia between 2011 and 2015. Malar J. 2020;19(1):20.

Chu CS, Bancone G, Kelley M, Advani N, Domingo GJ, Cutiongo-de la Paz EM, et al. Optimizing G6PD testing for Plasmodium vivax case management and beyond: why sex, counseling, and community engagement matter. Wellcome Open Res. 2020;5:21.

Coelho CH, Nadakal ST, Gonzales HP, Morrison R, Galson JD, Neal J, et al. Antimalarial antibody repertoire defined by plasma IG proteomics and single B cell IG sequencing. JCI.Insight. 2020;5(22).

Conner RO, Dieye Y, Hainsworth M, Tall A, Cissé B, Faye F, et al. Correction to: Mass testing and treatment for malaria followed by weekly fever screening, testing and treatment in Northern Senegal: feasibility, cost and impact. Malar J. 2020;19(1):443.

Conner RO, Dieye Y, Hainsworth M, Tall A, Cissé B, Faye F, et al. Mass testing and treatment for malaria followed by weekly fever screening, testing and treatment in Northern Senegal: feasibility, cost and impact. Malar J. 2020;19(1):252.

Daniels RF, Schaffner SF, Dieye Y, Dieng G, Hainsworth M, Fall FB, et al. Genetic evidence for imported malaria and local transmission in Richard Toll, Senegal. Malar J. 2020;19(1):276.

Du Y, Thompson EG, Muller J, Valvo J, Braun J, Shankar S, et al. The Ratiometric Transcript Signature MX2/GPR183 Is Consistently Associated With RTS,S-Mediated Protection Against Controlled Human Malaria Infection. Front.Immunol. 2020;11:669.

Galactionova K, Velarde M, Silumbe K, Miller J, McDonnell A, Aguas R, et al. Costing malaria interventions from pilots to elimination programmes. Malar J. 2020;19(1):332.

Galatas B, Mayor A, Gupta H, Balanza N, Jang IK, Nhamussua L, et al. Field performance of ultrasensitive and conventional malaria rapid diagnostic tests in southern Mozambique. Malar J. 2020;19(1):451.

Gogue C, Wagman J, Tynuv K, Saibu A, Yihdego Y, Malm K, et al. An observational analysis of the impact of indoor residual spraying in Northern, Upper East, and Upper West Regions of Ghana: 2014 through 2017. Malar J. 2020;19(1):242.

Guiguemde KT, Dieye Y, Lô AC, Ndiaye M, Lam A, Manga IA, et al. Molecular detection and quantification of Plasmodium falciparum gametocytes carriage in used RDTs in malaria elimination settings in northern Senegal. Malar J. 2020;19(1):123.

Huang WC, Deng B, Seffouh A, Ortega J, Long CA, Suresh RV, et al. Antibody response of a particle-inducing, liposome vaccine adjuvant admixed with a Pfs230 fragment. NPJ Vaccines. 2020;5(1):23.

Huang WC, Deng B, Mabrouk MT, Seffouh A, Ortega J, Long C, et al. Particle-based, Pfs230 and Pfs25 immunization is effective, but not improved by duplexing at fixed total antigen dose. Malar J. 2020;19(1):309.

Jang IK, Tyler A, Lyman C, Rek JC, Arinaitwe E, Adrama H, et al. Multiplex Human Malaria Array: Quantifying Antigens for Malaria Rapid Diagnostics. Am J Trop Med Hyg. 2020;102(6):1366–1369.

Kaslow DC. Malaria vaccine research & innovation: the intersection of IA2030 and zero malaria. NPJ Vaccines. 2020;5(1):109.

Lee SM, Hickey JM, Miura K, Joshi SB, Volkin DB, King CR, et al. A C-terminal Pfs48/45 malaria transmission-blocking vaccine candidate produced in the baculovirus expression system. Sci Rep. 2020;10(1):395.

Moon JE, Ockenhouse C, Regules JA, Vekemans J, Lee C, Chuang I, et al. A Phase IIa Controlled Human Malaria Infection and Immunogenicity Study of RTS,S/AS01E and RTS,S/AS01B Delayed Fractional Dose Regimens in Malaria-Naive Adults. J Infect Dis. 2020;222(10):1681–1691.

Oyen D, Torres JL, Aoto PC, Flores-Garcia Y, Binter Å, Pholcharee T, et al. Structure and mechanism of monoclonal antibody binding to the junctional epitope of Plasmodium falciparum circumsporozoite protein. PLoS Pathog. 2020;16(3):e1008373.

Pallikkuth S, Chaudhury S, Lu P, Pan L, Jongert E, Wille-Reece U, et al. A delayed fractionated dose RTS,S AS01 vaccine regimen mediates protection via improved T follicular helper and B cell responses. Elife. 2020;9.

Pfeffer DA, Ley B, Howes RE, Adu P, Alam MS, Bansil P, et al. Quantification of glucose-6-phosphate dehydrogenase activity by spectrophotometry: A systematic review and meta-analysis. PLoS Med. 2020;17(5):e1003084.

Phillips DE, Ambrosio G, Batzel A, Cerezo C, Duber H, Faye A, et al. Bringing a health systems modelling approach to complex evaluations: multicountry applications in HIV, TB and malaria. BMJ Glob Health. 2020;5(11).

Pholcharee T, Oyen D, Torres JL, Flores-Garcia Y, Martin GM, González-Páez GE, et al. Diverse Antibody Responses to Conserved Structural Motifs in Plasmodium falciparum Circumsporozoite Protein. J Mol.Biol. 2020;432(4):1048–1063.

Raghunandan R, Mayer BT, Flores-Garcia Y, Gerber MW, Gottardo R, Jhun H, et al. Characterization of two in vivo challenge models to measure functional activity of monoclonal antibodies to Plasmodium falciparum circumsporozoite protein. Malar J. 2020;19(1):113.

Reichert EN, Hume JCC, Sagara I, Healy SA, Assadou MH, Guindo MA, et al. Ultra-sensitive RDT performance and antigen dynamics in a high-transmission Plasmodium falciparum setting in Mali. Malar J . 2020;19(1):323.

Reuling IJ, Mendes AM, de Jong GM, Fabra-García A, Nunes-Cabaço H, van Gemert GJ, et al. An open-label phase 1/2a trial of a genetically modified rodent malaria parasite for immunization against Plasmodium falciparum malaria. Sci Transl.Med. 2020;12(544).

Shelley KD, Kamya C, Mpanya G, Mulongo S, Nagasha SN, Beylerian E, et al. Partnership and Participation-A Social Network Analysis of the 2017 Global Fund Application Process in the Democratic Republic of the Congo and Uganda. Ann Glob Health. 2020;86(1):140.

Sherrard-Smith E, Hogan AB, Hamlet A, Watson OJ, Whittaker C, Winskill P, et al. The potential public health consequences of COVID-19 on malaria in Africa. Nat Med. 2020;26(9):1411–1416.

Singh SK, Plieskatt J, Chourasia BK, Singh V, Bolscher JM, Dechering KJ, et al. The Plasmodium falciparum circumsporozoite protein produced in Lactococcus lactis is pure and stable. J Biol.Chem. 2020;295(2):403–414.

Singh SK, Plieskatt J, Chourasia BK, Fabra-García A, Garcia-Senosiain A, Singh V, et al. A Reproducible and Scalable Process for Manufacturing a Pfs48/45 Based Plasmodium falciparum Transmission-Blocking Vaccine. Front.Immunol. 2020;11:606266.

Sitali L, Mwenda MC, Miller JM, Bridges DJ, Hawela MB, Hamainza B, et al. Surveillance of molecular markers for antimalarial resistance in Zambia: Polymorphism of Pfkelch 13, Pfmdr1 and Pfdhfr/Pfdhps genes. Acta Trop. 2020;212:105704.

Slater HC, Foy BD, Kobylinski K, Chaccour C, Watson OJ, Hellewell J, et al. Ivermectin as a novel complementary malaria control tool to reduce incidence and prevalence: a modelling study. Lancet Infect Dis. 2020;20(4):498–508.

Stresman G, Sepúlveda N, Fornace K, Grignard L, Mwesigwa J, Achan J, et al. Association between the proportion of Plasmodium falciparum and Plasmodium vivax infections detected by passive surveillance and the magnitude of the asymptomatic reservoir in the community: a pooled analysis of paired health facility and community data. Lancet Infect Dis. 2020;20(8):953–963.

Stresman G, Whittaker C, Slater HC, Bousema T, Cook J. Quantifying Plasmodium falciparum infections clustering within households to inform household-based intervention strategies for malaria control programs: An observational study and meta-analysis from 41 malaria-endemic countries. PLoS Med. 2020;17(10):e1003370.

Suscovich TJ, Fallon JK, Das J, Demas AR, Crain J, Linde CH, et al. Mapping functional humoral correlates of protection against malaria challenge following RTS,S/AS01 vaccination. Sci Transl.Med. 2020;12(553).

Tandon R, Spark-DePass E, Sharma A, Gerth-Guyette E, Slutsker L, Daumerie PG, et al. Malaria radical cure opportunity assessment in India: Discussing opportunities through stakeholder convening workshop and recommendation for improved access to malaria treatment. J Vector Borne.Dis. 2020;57(2):182–186.

Thompson HA, Hogan AB, Walker PGT, White MT, Cunnington AJ, Ockenhouse CF, et al. Modelling the roles of antibody titre and avidity in protection from Plasmodium falciparum malaria infection following RTS,S/AS01 vaccination. Vaccine. 2020;38(47):7498–7507.

von SL, Hanboonkunupakarn B, Jittamala P, Pongsuwan P, Chotivanich K, Tarning J, et al. Combining antimalarial drugs and vaccine for malaria elimination campaigns: a randomized safety and immunogenicity trial of RTS,S/AS01 administered with dihydroartemisinin, piperaquine, and primaquine in healthy Thai adult volunteers. Hum.Vaccin Immunother. 2020;16(1):33–41.

Wagman J, Cissé I, Kone D, Fomba S, Eckert E, Mihigo J, et al. Combining next-generation indoor residual spraying and drug-based malaria control strategies: observational evidence of a combined effect in Mali. Malar J. 2020;19(1):293.

Wagman J, Cissé I, Kone D, Fomba S, Eckert E, Mihigo J, et al. Rapid reduction of malaria transmission following the introduction of indoor residual spraying in previously unsprayed districts: an observational analysis of Mopti Region, Mali, in 2017. Malar J. 2020;19(1):340.

Walker PGT, Cairns M, Slater H, Gutman J, Kayentao K, Williams JE, et al. Modelling the incremental benefit of introducing malaria screening strategies to antenatal care in Africa. Nat Commun. 2020;11(1):3799.

Woodford J, Collins KA, Odedra A, Wang C, Jang IK, Domingo GJ, et al. An Experimental Human Blood-Stage Model for Studying Plasmodium malariae Infection. J Infect Dis. 2020;221(6):948–955.


Alombah F, Eliades MJ, Wun J, Kutumbakana S, Mwinga R, Saye R, et al. Effect of Supportive Supervision on Malaria Microscopy Competencies in Sub-Saharan Africa. Am J Trop Med Hyg. 2019;100(4):868–875.

Alonso S, Chaccour CJ, Elobolobo E, Nacima A, Candrinho B, Saifodine A, et al. The economic burden of malaria on households and the health system in a high transmission district of Mozambique. Malar J. 2019;18(1):360.

Bancone G, Menard D, Khim N, Kim S, Canier L, Nguong C, et al. Molecular characterization and mapping of glucose-6-phosphate dehydrogenase (G6PD) mutations in the Greater Mekong Subregion. Malar J. 2019;18(1):20.

Burnett SM, Wun J, Evance I, Davis KM, Smith G, Lussiana C, et al. Introduction and Evaluation of an Electronic Tool for Improved Data Quality and Data Use during Malaria Case Management Supportive Supervision. Am J Trop Med Hyg. 2019;100(4):889–898.

Camponovo F, Ockenhouse CF, Lee C, Penny MA. Mass campaigns combining antimalarial drugs and anti-infective vaccines as seasonal interventions for malaria control, elimination and prevention of resurgence: a modelling study. BMC Infect Dis. 2019;19(1):920.

Chawla B, Mahajan B, Oakley M, Majam VF, Belmonte A, Sedegah M, et al. Antibody-Dependent, Gamma Interferon-Independent Sterilizing Immunity Induced by a Subunit Malaria Vaccine. Infect Immun. 2019;87(10).

Chitnis N, Pemberton-Ross P, Yukich J, Hamainza B, Miller J, Reiker T, et al. Theory of reactive interventions in the elimination and control of malaria. Malar J. 2019;18(1):266.

Domingo GJ, Advani N, Satyagraha AW, Sibley CH, Rowley E, Kalnoky M, et al. Addressing the gender-knowledge gap in glucose-6-phosphate dehydrogenase deficiency: challenges and opportunities. Int Health. 2019;11(1):7–14.

Eliades MJ, Alombah F, Wun J, Burnett SM, Clark T, Ntumy R, et al. Perspectives on Implementation Considerations and Costs of Malaria Case Management Supportive Supervision. Am J Trop Med Hyg. 2019;100(4):861–867.

Eliades MJ, Wun J, Burnett SM, Alombah F, moo-Sakyi F, Chirambo P, et al. Effect of Supportive Supervision on Performance of Malaria Rapid Diagnostic Tests in Sub-Saharan Africa. Am J Trop Med Hyg. 2019;100(4):876–881.

Flores-Garcia Y, Herrera SM, Jhun H, Pérez-Ramos DW, King CR, Locke E, et al. Optimization of an in vivo model to study immunity to Plasmodium falciparum pre-erythrocytic stages. Malar J. 2019;18(1):426.

Foy BD, Rao S, Parikh S, Slater HC, Dabiré RK. Analysis of the RIMDAMAL trial - Authors' reply. Lancet. 2019;394(10203):1006–1007.

Giersing BK, Vekemans J, Nava S, Kaslow DC, Moorthy V. Report from the World Health Organization's third Product Development for Vaccines Advisory Committee (PDVAC) meeting, Geneva, 8-10th June 2016. Vaccine. 2019;37(50):7315–7327.

Greenhouse B, Daily J, Guinovart C, Goncalves B, Beeson J, Bell D, et al. Priority use cases for antibody-detecting assays of recent malaria exposure as tools to achieve and sustain malaria elimination. Gates.Open Res. 2019;3:131.

Jang IK, Tyler A, Lyman C, Kahn M, Kalnoky M, Rek JC, et al. Simultaneous Quantification of Plasmodium Antigens and Host Factor C-Reactive Protein in Asymptomatic Individuals with Confirmed Malaria by Use of a Novel Multiplex Immunoassay. J Clin Microbiol. 2019;57(1).

Kavle JA, Pacqué M, Dalglish S, Mbombeshayi E, Anzolo J, Mirindi J, et al. Strengthening nutrition services within integrated community case management (iCCM) of childhood illnesses in the Democratic Republic of Congo: Evidence to guide implementation. Matern Child Nutr. 2019;15 Suppl 1(Suppl 1):e12725.

Lee SM, Plieskatt J, Krishnan S, Raina M, Harishchandra R, King CR. Expression and purification optimization of an N-terminal Pfs230 transmission-blocking vaccine candidate. Protein Expr.Purif. 2019;160:56–65.

Lee SM, Wu Y, Hickey JM, Miura K, Whitaker N, Joshi SB, et al. The Pfs230 N-terminal fragment, Pfs230D1+: expression and characterization of a potential malaria transmission-blocking vaccine candidate. Malar J. 2019;18(1):356.

Martin T, Eliades MJ, Wun J, Burnett SM, Alombah F, Ntumy R, et al. Effect of Supportive Supervision on Competency of Febrile Clinical Case Management in Sub-Saharan Africa. Am J Trop Med Hyg. 2019;100(4):882–888.

McLeod B, Miura K, Scally SW, Bosch A, Nguyen N, Shin H, et al. Potent antibody lineage against malaria transmission elicited by human vaccination with Pfs25. Nat Commun. 2019;10(1):4328.

Miura K, Deng B, Wu Y, Zhou L, Pham TP, Diouf A, et al. ELISA units, IgG subclass ratio and avidity determined functional activity of mouse anti-Pfs230 antibodies judged by a standard membrane-feeding assay with Plasmodium falciparum. Vaccine. 2019;37(15):2073–2078.

Mwesigwa J, Slater H, Bradley J, Saidy B, Ceesay F, Whittaker C, et al. Field performance of the malaria highly sensitive rapid diagnostic test in a setting of varying malaria transmission. Malar J. 2019;18(1):288.

Pal S, Bansil P, Bancone G, Hrutkay S, Kahn M, Gornsawun G, et al. Evaluation of a Novel Quantitative Test for Glucose-6-Phosphate Dehydrogenase Deficiency: Bringing Quantitative Testing for Glucose-6-Phosphate Dehydrogenase Deficiency Closer to the Patient. Am J Trop Med Hyg. 2019;100(1):213–221.

Sitali L, Miller JM, Mwenda MC, Bridges DJ, Hawela MB, Hamainza B, et al. Distribution of Plasmodium species and assessment of performance of diagnostic tools used during a malaria survey in Southern and Western Provinces of Zambia. Malar J. 2019;18(1):130.

Sitali L, Mwenda MC, Miller JM, Bridges DJ, Hawela MB, Chizema-Kawesha E, et al. En-route to the 'elimination' of genotypic chloroquine resistance in Western and Southern Zambia, 14Â years after chloroquine withdrawal. Malar J. 2019;18(1):391.

Slater HC, Ross A, Felger I, Hofmann NE, Robinson L, Cook J, et al. The temporal dynamics and infectiousness of subpatent Plasmodium falciparum infections in relation to parasite density. Nat Commun. 2019;10(1):1433.

Slater HC, Ross A, Felger I, Hofmann NE, Robinson L, Cook J, et al. Author Correction: The temporal dynamics and infectiousness of subpatent Plasmodium falciparum infections in relation to parasite density. Nat Commun. 2019;10(1):2644.

Tachibana M, Miura K, Takashima E, Morita M, Nagaoka H, Zhou L, et al. Identification of domains within Pfs230 that elicit transmission blocking antibody responses. Vaccine. 2019;37(13):1799–1806.


Anderle A, Bancone G, Domingo GJ, Gerth-Guyette E, Pal S, Satyagraha AW. Point-of-Care Testing for G6PD Deficiency: Opportunities for Screening. Int J Neonatal Screen. 2018;4(4):34.

Bancone G, Gornsawun G, Chu CS, Porn P, Pal S, Bansil P, et al. Validation of the quantitative point-of-care CareStart biosensor for assessment of G6PD activity in venous blood. PLoS One. 2018;13(5):e0196716.

Bansil P, Yeshiwondim AK, Guinovart C, Serda B, Scott C, Tesfay BH, et al. Malaria case investigation with reactive focal testing and treatment: operational feasibility and lessons learned from low and moderate transmission areas in Amhara Region, Ethiopia. Malar J. 2018;17(1):449.

Burrows J, Slater H, Macintyre F, Rees S, Thomas A, Okumu F, et al. A discovery and development roadmap for new endectocidal transmission-blocking agents in malaria. Malar J. 2018;17(1):462.

Burton RA, Chévez JER, Sauerbrey M, Guinovart C, Hartley A, Kirkwood G, et al. Factors Associated with the Rapid and Durable Decline in Malaria Incidence in El Salvador, 1980-2017. Am J Trop Med Hyg. 2018;99(1):33–42.

Chaccour CJ, Alonso S, Zulliger R, Wagman J, Saifodine A, Candrinho B, et al. Combination of indoor residual spraying with long-lasting insecticide-treated nets for malaria control in Zambezia, Mozambique: a cluster randomised trial and cost-effectiveness study protocol. BMJ Glob Health. 2018;3(1):e000610.

Chichester JA, Green BJ, Jones RM, Shoji Y, Miura K, Long CA, et al. Safety and immunogenicity of a plant-produced Pfs25 virus-like particle as a transmission blocking vaccine against malaria: A Phase 1 dose-escalation study in healthy adults. Vaccine. 2018;36(39):5865–5871.

Das S, Peck RB, Barney R, Jang IK, Kahn M, Zhu M, et al. Performance of an ultra-sensitive Plasmodium falciparum HRP2-based rapid diagnostic test with recombinant HRP2, culture parasites, and archived whole blood samples. Malar J. 2018;17(1):118.

Dennison SM, Reichartz M, Seaton KE, Dutta S, Wille-Reece U, Hill AVS, et al. Qualified Biolayer Interferometry Avidity Measurements Distinguish the Heterogeneity of Antibody Interactions with Plasmodium falciparum Circumsporozoite Protein Antigens. J Immunol. 2018;201(4):1315–1326.

Draper SJ, Sack BK, King CR, Nielsen CM, Rayner JC, Higgins MK, et al. Malaria Vaccines: Recent Advances and New Horizons. Cell Host.Microbe. 2018;24(1):43–56.

Early AM, Lievens M, MacInnis BL, Ockenhouse CF, Volkman SK, Adjei S, et al. Host-mediated selection impacts the diversity of Plasmodium falciparum antigens within infections. Nat Commun. 2018;9(1):1381.

Huang WC, Deng B, Lin C, Carter KA, Geng J, Razi A, et al. A malaria vaccine adjuvant based on recombinant antigen binding to liposomes. Nat Nanotechnol. 2018;13(12):1174–1181.

Jang IK, Das S, Barney RS, Peck RB, Rashid A, Proux S, et al. A new highly sensitive enzyme-linked immunosorbent assay for the detection of Plasmodium falciparum histidine-rich protein 2 in whole blood. Malar J. 2018;17(1):403.

Kalnoky M, Bancone G, Kahn M, Chu CS, Chowwiwat N, Wilaisrisak P, et al. Cytochemical flow analysis of intracellular G6PD and aggregate analysis of mosaic G6PD expression. Eur J Haematol. 2018;100(3):294–303.

Kapoor N, Vanjak I, Rozzelle J, Berges A, Chan W, Yin G, et al. Malaria Derived Glycosylphosphatidylinositol Anchor Enhances Anti-Pfs25 Functional Antibodies That Block Malaria Transmission. Biochemistry. 2018;57(5):516–519.

Kundu P, Semesi A, Jore MM, Morin MJ, Price VL, Liang A, et al. Structural delineation of potent transmission-blocking epitope I on malaria antigen Pfs48/45. Nat Commun. 2018;9(1):4458.

Landier J, Haohankhunnatham W, Das S, Konghahong K, Christensen P, Raksuansak J, et al. Operational Performance of a Plasmodium falciparum Ultrasensitive Rapid Diagnostic Test for Detection of Asymptomatic Infections in Eastern Myanmar. J Clin Microbiol. 2018;56(8).

Lee SM, Plieskatt J, King CR. Disulfide bond mapping of Pfs25, a recombinant malaria transmission blocking vaccine candidate. Anal Biochem. 2018;542:20–23.

Lee SM, Plieskatt JL, King CR. Peptide data on the disulfide bond analysis of baculovirus produced Pfs25 by LC-MSMS. Data.Brief. 2018;18:209–233.

Masaninga F, Mukumbuta N, Ndhlovu K, Hamainza B, Wamulume P, Chanda E, et al. Insecticide-treated nets mass distribution campaign: benefits and lessons in Zambia. Malar J. 2018;17(1):173.

Mendes AM, Reuling IJ, Andrade CM, Otto TD, Machado M, Teixeira F, et al. Pre-clinical evaluation of a P. berghei-based whole-sporozoite malaria vaccine candidate. NPJ Vaccines. 2018;3:54.

Nielsen CM, Vekemans J, Lievens M, Kester KE, Regules JA, Ockenhouse CF. RTS,S malaria vaccine efficacy and immunogenicity during Plasmodium falciparum challenge is associated with HLA genotype. Vaccine. 2018;36(12):1637–1642.

Oakley MS, Verma N, Myers TG, Zheng H, Locke E, Morin MJ, et al. Transcriptome analysis based detection of Plasmodium falciparum development in Anopheles stephensi mosquitoes. Sci Rep. 2018;8(1):11568.

Othman AS, Lin JW, Franke-Fayard BM, Kroeze H, van Pul FJA, Chevalley-Maurel S, et al. Expression of full-length Plasmodium falciparum P48/45 in P. berghei blood stages: A method to express and evaluate vaccine antigens. Mol.Biochem Parasitol. 2018;224:44–49.

Oyen D, Torres JL, Cottrell CA, Richter KC, Wilson IA, Ward AB. Cryo-EM structure of P. falciparum circumsporozoite protein with a vaccine-elicited antibody is stabilized by somatically mutated inter-Fab contacts. Sci Adv. 2018;4(10):eaau8529.

Rampling T, Ewer KJ, Bowyer G, Edwards NJ, Wright D, Sridhar S, et al. Safety and efficacy of novel malaria vaccine regimens of RTS,S/AS01B alone, or with concomitant ChAd63-MVA-vectored vaccines expressing ME-TRAP. NPJ Vaccines. 2018;3:49.

Reuling IJ, van de Schans LA, Coffeng LE, Lanke K, Meerstein-Kessel L, Graumans W, et al. A randomized feasibility trial comparing four antimalarial drug regimens to induce Plasmodium falciparum gametocytemia in the controlled human malaria infection model. Elife. 2018;7.

Routledge I, Chevéz JER, Cucunubá ZM, Rodriguez MG, Guinovart C, Gustafson KB, et al. Estimating spatiotemporally varying malaria reproduction numbers in a near elimination setting. Nat Commun. 2018;9(1):2476.

Sarkar D, Murphy H, Fisseha T, Koroma AS, Hodges MH, Adero N, et al. Understanding the process of strengthening multi-sectoral efforts for anemia reduction: Qualitative findings from Sierra Leone and Uganda. Int J Health Plann Manage. 2018;33(4):1024–1044.

Sherrard-Smith E, Sala KA, Betancourt M, Upton LM, Angrisano F, Morin MJ, et al. Synergy in anti-malarial pre-erythrocytic and transmission-blocking antibodies is achieved by reducing parasite density. Elife. 2018;7.

Thompson EA, Ols S, Miura K, Rausch K, Narum DL, Spångberg M, et al. TLR-adjuvanted nanoparticle vaccines differentially influence the quality and longevity of responses to malaria antigen Pfs25. JCI.Insight. 2018;3(10).

Thriemer K, Bobogare A, Ley B, Gudo CS, Alam MS, Anstey NM, et al. Quantifying primaquine effectiveness and improving adherence: a round table discussion of the APMEN Vivax Working Group. Malar J . 2018;17(1):241.

Tiruneh M, Gebregergs GB, Birhanu D. Determinants of delay in seeking treatment among malaria patients in Dera district, NorthWest Ethiopia: a case control study. Afr Health Sci. 2018;18(3):552–559.

Wagman J, Gogue C, Tynuv K, Mihigo J, Bankineza E, Bah M, et al. An observational analysis of the impact of indoor residual spraying with non-pyrethroid insecticides on the incidence of malaria in Ségou Region, Mali: 2012-2015. Malar J. 2018;17(1):19.

Zemene E, Koepfli C, Tiruneh A, Yeshiwondim AK, Seyoum D, Lee MC, et al. Detection of foci of residual malaria transmission through reactive case detection in Ethiopia. Malar J. 2018;17(1):390.